Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
|
|
Adverum Biotechnologies, Inc. (ADVM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/24/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/09/2023 |
4
| Rubinstein Linda M (CFO) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Bought 100,000 shares
@ $1.4549, valued at
$145.5k
|
|
| 05/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/19/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/25/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/17/2023 |
4
| Riley Brigit (Chief Scientific Officer) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Sold 7,299 shares
@ $0.7816, valued at
$5.7k
|
|
| 03/17/2023 |
4
| Soparkar Peter (COO) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Sold 13,360 shares
@ $0.7816, valued at
$10.4k
|
|
| 03/17/2023 |
4
| Fischer Laurent (CEO, President and Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Sold 41,239 shares
@ $0.7816, valued at
$32.2k
|
|
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G
| BANK OF AMERICA CORP reports a 5.6% stake in Adverum Biotechnologies, Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 7.8% stake in ADVERUM BIOTECHNOLOGIES INC |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 7.3% stake in Adverum Biotechnologies, Inc. |
| 02/08/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/30/2022 |
SC 13D/A
| Sonic Fund II, L.P. reports a 4.6% stake in Adverum Biotechnologies, Inc. |
| 12/15/2022 |
3
| Rubinstein Linda M (CFO) has filed a Form 3 on Adverum Biotechnologies, Inc. |
| 12/13/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
|
|
|